HealthEquity
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 4 Sell calls were actually followed by a +19% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -7.5% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 6.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 34.2x | Better than 18% |
| Forward P/E | 31.9x | Better than 16% |
| Price / Sales | 6.3x | Better than 17% |
| P/E vs own 5-yr range | 48th pctl | Better than 62% |
Growth A+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 15.1% | Better than 76% |
| Net income CAGR (3Y) | 84.8% | Better than 94% |
| Free cash flow CAGR (3Y) | 134.8% | Better than 96% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 69.5% | Better than 83% |
| Operating margin | 24.9% | Better than 84% |
| Net margin | 16.4% | Better than 74% |
| Return on equity | 10.2% | Better than 53% |
| Return on invested capital | 7.9% | Better than 60% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -10.1% | Better than 50% |
| 6-month return | 7.5% | Better than 69% |
| 12-month return (ex latest month) | -0.9% | Better than 32% |
| Distance below 52-week high | 14.1% | Better than 74% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.3x | Better than 76% |
| Debt to assets | 29.6% | Better than 42% |
| Interest coverage | 5.9x | Better than 60% |
| Free cash flow / net income | 189.7% | Better than 75% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 27.8% | Better than 45% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 97.38
- Open
- 97.66
- Day range
- 94.37 - 99.46
- Avg price
- 96.00
- Volume
- 741.34K
- Turnover
- 71.17M
- Turnover ratei
- 0.92%
- Volume ratioi
- 0.87
- Amplitudei
- 5.23%
- 52-week rangei
- 72.76 - 110.26
Valuation
- P/Ei
- 38.52
- P/E (TTM)i
- 34.21
- P/Bi
- 3.94
- EPSi
- 2.46
- Book value / shi
- 24.06
- Net profit
- 203.48M
- Net assets
- 1.99B
Share structure
- Market cap
- 7.84B
- Float capi
- 7.67B
- Shares out
- 82.72M
- Float sharesi
- 80.97M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
14.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-5.22M net over the window
Short interest
- Shares short
- 5.48M
- % of floati
- 6.62%
- Days to coveri
- 7.55
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of HealthEquity (HQY)?
HealthEquity last traded at 94.75. This page shows a periodic quote snapshot. Check the displayed quote time.
What is HealthEquity's market cap?
About 7.84B.
What is the P/E ratio of HealthEquity?
The trailing twelve-month P/E is 34.21, above its own 5-year average of 1.80 — in the middle of its historical range (48.33% percentile). See the Valuation tab for the full history.
Does HealthEquity pay a dividend?
HealthEquity does not currently pay a regular dividend.
Is HealthEquity a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 121.11, which implies 27.8% upside from the current price. This is not investment advice.
What is HealthEquity's StockVane Quant Rating?
The StockVane Momentum strategy currently rates HealthEquity a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
HealthEquity discussion 0 comments